Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9726206 | 0.92 | HTR2A (0.62) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9726221 | 0.91 | HTR2A (0.64) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL4850144 | 0.79 | HTR2A (0.47) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9726243 | 0.76 | HTR1A (0.64) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9726193 | 0.74 | HTR7 (0.73) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9726205 | 0.74 | HTR2A (0.70) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9726198 | 0.74 | DRD2 (0.70) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9726239 | 0.74 | HTR2A (0.57) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL9283602 | 0.68 | HTR2A (0.39) | HTR2AHTR1ADRD2HTR7HTR6 | |
| SCHEMBL24327018 | 0.66 | HTR2A (0.43) | HTR2AHTR1ADRD2HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | disclosed |
| US-5130313-A | Central nervous system disorders, cardiovascular disorders or gastrointestinal disorders | RHONE-POULENC SANTE (FR) | 1992-07-14 | — | — | US | disclosed |
| US-5114949-A | Treating disorders associated with 5HT uptake | RHONE-POULENC SANTE (FR) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053783-A1 | Central nervous system disorders | CNR1, PMP22, CNR2 | HTR2A 332/4885HTR1A 42/4885DRD2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.